Parkside Financial Bank & Trust Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Parkside Financial Bank & Trust raised its position in DexCom, Inc. (NASDAQ:DXCM) by 11.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,086 shares of the medical device company’s stock after buying an additional 218 shares during the period. Parkside Financial Bank & Trust’s holdings in DexCom were worth $259,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Valley National Advisers Inc. boosted its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. MV Capital Management Inc. boosted its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the last quarter. Washington Trust Advisors Inc. boosted its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares during the last quarter. NBC Securities Inc. acquired a new position in DexCom in the 3rd quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom in the 3rd quarter valued at about $48,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Raymond James increased their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $141.40.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock worth $25,530,859 over the last 90 days. Insiders own 0.41% of the company’s stock.

DexCom Stock Up 1.5 %

Shares of DXCM traded up $2.03 during mid-day trading on Wednesday, reaching $136.03. 1,069,893 shares of the stock traded hands, compared to its average volume of 2,934,131. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The stock has a fifty day simple moving average of $130.15 and a 200 day simple moving average of $117.74. The firm has a market cap of $52.44 billion, a price-to-earnings ratio of 102.29, a P/E/G ratio of 2.26 and a beta of 1.20. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business’s revenue was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.34 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.